Format

Send to

Choose Destination
Thromb Haemost. 2014 Jul 3;112(1):26-31. doi: 10.1160/TH13-09-0756. Epub 2014 Feb 20.

Implications of glycoprotein VI for theranostics.

Author information

1
Meinrad Gawaz, MD, Department of Cardiology, University of Tübingen, Otfried-Müller-Straße 10, 72076 Tübingen, Germany, Tel.: +49 7071 29 83688, Fax: +49 7071 29 5749, E-mail: meinrad.gawaz@med.uni-tuebingen.de.

Abstract

Glycoprotein VI (GPVI), a membrane glycoprotein solely expressed in platelets and megakaryocytes, plays a critical role in thrombus formation due to collagen/GPVI-mediated platelet activation and adhesion. Recent studies have shown that surface expression of GPVI on circulating platelets is enhanced in acute cardiovascular diseases such as myocardial infarction and ischaemic stroke. Increased GPVI levels are associated with poor clinical outcome and are an early indicator for imminent myocardial infarction in patients with chest pain. The soluble form of the dimeric GPVI fusion protein (sGPVI-Fc) binds with high affinity to collagen and atherosclerotic plaque tissue. Non-invasive imaging studies with radiolabelled sGPVI-Fc show specific binding activity to vascular lesions in vivo. Further, sGPVI-Fc has been developed as a new therapeutic platelet-based strategy for lesion-directed antithrombotic therapy. This review summarises the potential of GPVI for diagnostic and therapeutic options based on novel non-invasive molecular imaging modalities to ameliorate care of patients with cardiovascular diseases.

KEYWORDS:

Platelets; biomarker; glycoprotein VI; molecular imaging; myocardial infarction; stroke

PMID:
24553806
DOI:
10.1160/TH13-09-0756
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center